scholarly journals Serum folate levels in end stage renal disease patients

2016 ◽  
Vol 11 (3) ◽  
Author(s):  
Ghazanfar Ali Sirhindi ◽  
Saadia Shahzad Alam ◽  
Shahida Amjad Riaz Shah ◽  
Javed Asif ◽  
Mateen Izhar ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Serum Folate ◽  
Control Group ◽  
Folate Level ◽  
Healthy Individuals ◽  
Serum Folate Level ◽  
Group B ◽  
Stage Renal Disease ◽  
End Stage

Objective: This study was aimed to measure serum folate levels in patients of end stage renal disease (ESRD) on regular haemodialysis and compared with normal healthy individuals. Study design: It is a comparative study. Setting: Department of Pathology, Shaikh Zayed Hospital, Lahore Patients and methods: One hundred subjects were selected and divided into two groups. Group A include fifty patients of end stage renal disease on regular haemodialysis and group B include fifty normal healthy individuals as control. Two ml of blood was drawn by venepuncture, one ml for complete blood examination and one ml for serum folate level. Results: A significant decrease in folate level was observed in end stage renal disease patients on regular haemodialysis as compared to control group. Conclusion: By measuring serum folate level in patients on regular haemodialysis we can manage anaemia due to folate deficiency.

scholarly journals A comparative study of red cell folate and serum folate levels in patients on regular Hemodialysis

2016 ◽  
Vol 10 (4) ◽  
Author(s):  
Ikram Din Ujjan ◽  
Muhammad Tayyib ◽  
Tahira Tasneem ◽  
Muhammad Farooq ◽  
Muhammad Azhar Mughal ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Healthy Subjects ◽  
Serum Folate ◽  
Red Cell ◽  
Group A ◽  
Level Of Significance ◽  
Group B ◽  
Stage Renal Disease ◽  
End Stage

Sixty subjects were selected and were divided into two groups. Group A included 30 patients of end stage renal disease on regular dialysis and group B included 30 normal healthy subjects as control. Absolute values and Hb were done by hematology auto analyzer and serum and red cell folate were done by commercially available kits. Results were analyzed by using Student`s `t` test and level of significance was done. A significant decreased in serum and red cell folate in end stage renal disease patients with regular dialysis as compared to control.

The role of VEGF rs699947 polymorphism in End-Stage Renal Disease: A preliminary study

2021 ◽  
pp. 19-23
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Protective Factor ◽  
Public Health Problem ◽  
Turkish Population ◽  
Control Group ◽  
Case Group ◽  
Important Public Health Problem ◽  
Stage Renal Disease ◽  
End Stage

Aim: End-Stage Renal Disease (ESRD) is an important public health problem worldwide with an increasing incidence and prevalence. There are many environmental and genetic factors which contribute to the development of ESRD. Vascular endothelial growth factor (VEGF) has been suggested to play an important role in renal pathophysiology. The aim of this study was to determine the probable relation between ESRD and VEGF gene rs699947 polymorphism in Turkish population. Material and Method: Genotyping of rs699947 was carried out in 50 ESRD patients on dialysis treatment and 30 healthy controls, using a Kompetitive Allelic-Specific PCR (KASP) method following DNA isolation. Demographic and clinical characteristics of the patients were recorded. Results: The prevalance of rs699947 AA genotype was found to be higher in the control group, but it was not statistically significant (p>0.05) . Conclusion: Although statistically insignificant, the frequency of AA genotype was higher in the control group compared to the case group, therefore we concluded that AA genotype may be a protective factor for ESRD in Turkish population. However, this conclusion needs to be further verified by future studies performed in larger study groups.

scholarly journals Analysis of Endocan Levels in Hypertensive Patients as Risk Factors of Chronic Kidney Disease

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Suryani Jamal ◽  
Uleng Bahrun ◽  
Ibrahim Abdul Samad ◽  
Fitriani Mangarengi ◽  
Hasyim Kasim ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Ii ◽  
University Hospital ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Elisa Method ◽  
Cross Sectional ◽  
Stage Renal Disease ◽  
End Stage

This study aimed to analyze endocan levels as a marker of endothelial dysfunction in the control group, patients withstage I hypertension, stage II hypertension, and patients with end-stage renal disease. Endocan levels were measured withESM-1 (endocan) kit by Enzyme-Linked Immunosorbent Assay (ELISA) method. This study used a cross-sectional methodand was conducted in Dr. Wahidin Sudirohusodo Hospital, Makassar and Hasanuddin University Hospital from Septemberto October 2017. There were 83 samples in this study, consisting of 12 samples in the control group, 22 samples of stage Ihypertension, 28 samples of stage II hypertension, and 21 samples of end-stage renal disease aged 20-90 years old. Thisstudy showed significantly higher endocan levels in patients with stage II hypertension and end-stage renal disease(p< 0.05). Endocan levels were significantly higher (p<0.05) in patients with end-stage renal disease compared with thecontrol group and patients with stage I hypertension; but not significantly higher (p > 0.05) compared to patients with stageII hypertension. Also, the median of endocan levels in patients with the end-stage renal disease was higher (309,850 ng/L)compared to patients with stage II hypertension (273,050 ng/L).

scholarly journals Dyslipidemia in End Stage Renal Disease: A Study on Dialysis Patients in Bangabandhu Sheikh Mujib Medical University Bangladesh

KYAMC Journal ◽  
2020 ◽  
Vol 11 (3) ◽  
pp. 113-117
Author(s):  
Salahuddin Feroz ◽  
Shah Md Zakir Hossain ◽  
Rafi Nazrul Islam ◽  
Amir Mohammad Kaiser ◽  
Miliva Mozaffor ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hdl Cholesterol ◽  
Dialysis Patients ◽  
Ckd Stage ◽  
Group A ◽  
Group B ◽  
Stage Renal Disease ◽  
End Stage ◽  
Medical University

Background: Dyslipidemia contributes to the high cardiovascular risk in end stage renal disease (ESRD) or in dialysis patients; however, it remains an underestimated problem. Objective: To see the extent of dyslipidemia in patients of end stage renal disease i.e. chronic kidney disease (CKD) stage 5 who underwent hemodialysis or peritoneal dialysis procedure. Materials and Methods: This cross-sectional study was conducted from September 2016 to March 2018 Bangabandhu Sheikh Mujib Medical University (BSMMU) on 55 CKD (stage 5) patients where 31 in hemodialysis (HD) (group A) and 24 in continuous ambulatory peritoneal dialysis (CAPD) (group B). Serum lipid profile was estimated in both groups by using the standard laboratory technique. Results: Dialysis adequacy (Kt/V) was found 1.46 for HD patients (group A) and 1.81 for CAPD patients (group B).All serum lipids were higher in amount in CAPD patients than HD patients-total cholesterol (222.3±24.2 mg/dl vs. 198.9±28.4 mg/dl; p<0.05), triglycerides (179.6±24.7 mg/dl vs. 176.6±24.4 mg/dl; p<0.05), HDL cholesterol (40.8±3.90 mg/dl vs. 38.5±4.95 mg/dl; p>0.05) and LDL cholesterol (145.5±22.1 mg/dl vs. 123.2±26.5 mg/dl; p<0.05). Besides, dyslipidemia was more evident in CAPD patients than HD patients, as per raised serum total cholesterol (83.33% vs. 70.97%), raised triglycerides (95.83% vs. 83.87%), raised LDL (100% vs. 77.42%) and lowering of HDL cholesterol (87.5% vs. 80.65%) were found more in group B in comparison to group A. Conclusion: Dyslipidemic risk factors are highly evident in dialysis patients and the extent of dyslipidemia is observed more in CAPD than HD patients. KYAMC Journal Vol. 11, No.-3, October 2020, Page 113-117

Podocalyxin as an early marker predicting diabetic nephropathy and its correlation with stages of diabetic nephropathy in type two diabetic patients

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Salah El-Din A Shelbaya ◽  
Hanan M Ali ◽  
Rana H Ibrahim ◽  
Nourhan Safwat Sawirs
Keyword(s):  
Diabetic Nephropathy ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Control Group ◽  
Diabetic Patients ◽  
Type 2 Dm ◽  
Stage Renal Disease ◽  
End Stage ◽  
Positive Significant Correlation

Abstract Background Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Early identification of nephropathy in diabetes patients is crucial because it creates opportunity for preventing the incidence of DN and/or even slows down the process of end-stage renal disease attributed to diabetes. Human podocytes (Pods) have been demonstrated to be functionally and structurally injured in the natural history of diabetic nephropathy. Aim of the Work To evaluate the possible association between the urinary podocalyxin levels and severity and grade of diabetic nephropathy and to use urinary podocalyxin as a non-invasive marker for early stage of diabetic nephropathy in type 2 DM. Patients and Methods We collected 60 known clinically and biochemically type 2 diabetic patients.20 diabetic patients with no evidence of diabetic nephropathy, 20 patients diagnosed as diabetic nephropathy in microalbuminuria stages and 20 patients diagnosed as diabetic nephropathy in macroalbuminuria stages from Ain Shams University hospitals between April and December 2018 and 20 apparently healthy volunteers will included as a control group. Results Urinary PCX was significantly higher in patients group compared to control group. Urinary PCX was significantly higher in microalbuminuric group than in normoalbuminuric group and higher in macroalbuminuric group than in microalbuminuric group. There was a positive significant correlation between FBS, 2HrPP, HBA1C and urinary PCX. There was a positive significant correlation between s.create and urinary PCX. There was a positive significant correlation between ACR and urinary PCX. Conclusion Urinary podocalyxin seems to be beneficial as an early marker for early stages of diabetic nephropathy in type 2 DM patients.

scholarly journals P0312ALTERATIONS IN THE PROGRESS OF LYMPHOCYTE APOPTOSIS IN PRE- AND POST- DIALYSIS END STAGE RENAL DISEASE PATIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Dimitra Vasileia Daikidou ◽  
MARIA STANGOU ◽  
Erasmia Sampani ◽  
Despoina Asouchidou ◽  
Vasiliki Nikolaidou ◽  
...  
Keyword(s):  
B Cells ◽  
Renal Disease ◽  
B Lymphocytes ◽  
End Stage Renal Disease ◽  
Statistical Significance ◽  
Control Group ◽  
Apoptotic Cells ◽  
Lymphocyte Apoptosis ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background and Aims Lymphocyte apoptosis, as a programmed mechanism of lymphocyte death, is essential in maintaining homeostasis and balance between inflammatory and immune reactions. Disturbances in the apoptotic progress, leading to fragmented lymphocytes, “late apoptotic” cells, may result in immunodeficiency, oncogenesis, atheromatosis, etc. Aim of the present study was to investigate the lymphocyte apoptotic progress in End Stage Renal Disease (ESRD) and the effect of dialysis. Method The study included patients on ESRD; measurements were performed at the first day of dialysis (T0) and repeated 6 months later (T6), while being on dialysis. Total lymphocytes and B lymphocytes (CD19+) were gated and stained with Annexin V to detect apoptotic cells; early and late apoptotic cells were quantified. The results were compared to age-matched healthy control group. Results ESRD patients had reduced lymphocyte and B cell count, 1550±592μ/L vs. 2692±690μ/L, p&lt;0.001 and 120.4±80μ/L vs. 321.7±184.7μ/L, p=0.002, respectively, compared to controls. There was an increase in total lymphocytes and B cells, being on later apoptotic stages (LAS) in ESRD-T0 compared to controls, 0.3±0.8% vs. 0.06±0.1%, and 0.04±0.08% vs. 0.01±0.03%, respectively, although differences did not reach statistical significance. After 6 months on dialysis, a reduction was noticed in the population of lymphocytes on LAS, 0.18±0.2% from 0.34±0.8%, while there was an increase of B cells on LAS, 0.1±0.2% from 0.02±0.07, with subsequent alterations in total numbers of apoptotic cells were also evident Conclusion Late apoptotic changes affecting total and particularly B lymphocytes happen in ESRD, and initiation of dialysis seem to cause further alterations, which may be implicated in the increased morbidity and mortality of disease

Systemic lupus erythematosus diagnosis impacts clinical outcomes of arteriovenous fistulas in comparison to other end-stage renal disease etiologies

Vascular ◽  
2020 ◽  
pp. 170853812093640
Author(s):  
Cesar Cuen-Ojeda ◽  
Virginia Pascual-Ramos ◽  
Irazú Contreras-Yáñez ◽  
Javier E Anaya-Ayala ◽  
Erika Elenes-Sanchez ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Renal Disease ◽  
Lupus Erythematosus ◽  
End Stage Renal Disease ◽  
Primary Patency ◽  
Control Group ◽  
Systemic Lupus ◽  
Arteriovenous Fistulas ◽  
Stage Renal Disease ◽  
End Stage

Objectives Arteriovenous fistulas primary patency at one-year occurs in 43–85% of the patients with end-stage renal disease. The diagnosis attributable to end-stage renal disease has been suggested to impact arteriovenous fistulas outcomes. The objective was to compare primary patency at one week, 1, 3, 6, and 12 months of follow-ups, among systemic lupus erythematosus patients and two control groups; additionally, we evaluated the impact of systemic lupus erythematosus to predict early patency loss. Methods A retrospective review of charts from arteriovenous fistulas created between 2008 and 2017 was performed. One-hundred thirty-four patients were identified and classified according to end-stage renal disease attributable diagnosis as: systemic lupus erythematosus cases ( N = 14), control-group-1 (91 patients with primarily diabetes and hypertension), and control-group-2 (29 patients with idiopathic end-stage renal disease). A case–control matched design (1:2:1) was proposed. Logistic regression analysis and Kaplan–Meier curves were used. Institutional Review Board approval was obtained. Results More systemic lupus erythematosus patients lost primary patency at 3 (28.6%) and 12 months (71.4%) than patients from control-groups-1 (vs. 3.6% and 35.7%, respectively) and -2 (vs. 0% and 14.3%, respectively), ( p ≤ 0.011 for both). Days of primary patency survival were shorter in systemic lupus erythematosus patients ( p = 0.003). Systemic lupus erythematosus diagnosis was the only factor associated with early patency loss, HR: 3.141, 95%CI: 1.161–8.493 (systemic lupus erythematosus diagnosis vs. control-group-1) and HR: 12.582, 95%CI: 1.582–100.035 (systemic lupus erythematosus diagnosis vs. control-group-2). Conclusions Diagnosis attributable to end-stage renal disease has a major impact on arteriovenous fistula outcomes in patients. Systemic lupus erythematosus patients have an increased risk of arteriovenous fistulas patency loss within the first six months of follow-up. Patients with idiopathic end-stage renal disease had an excellent one year arteriovenous fistula patency survival.

scholarly journals Serum Folate and Homocysteine Levels Are Associated With Colon Tumorigenesis in End-Stage Renal Disease Patients

2011 ◽  
Vol 63 (2) ◽  
pp. 202-211 ◽  
Author(s):  
Eisuke Kaji ◽  
Jun Kato ◽  
Shunsuke Saito ◽  
Keita Harada ◽  
Kenji Kuwaki ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Serum Folate ◽  
Colon Tumorigenesis ◽  
Stage Renal Disease ◽  
End Stage

Mathematical Modelling of Erythropoiesis in Patients with End Stage Renal Disease: New Insights into Marrow Functioning

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3345-3345 ◽  
Author(s):  
Ashwani K Gupta ◽  
Ravneet Bajwa ◽  
Olivia Prosper ◽  
Maia Marchetva
Keyword(s):  
Peritoneal Dialysis ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cell Maturation ◽  
Clear Understanding ◽  
Healthy Individuals ◽  
Apparent Lack ◽  
Stage Renal Disease ◽  
End Stage

Abstract BACKGROUND Anemia is a well-recognized complication of chronic kidney disease (CKD). Shortened red blood cell (RBC) survival, uremic inhibitors of erythropoiesis and a relative deficiency of erythropoietin have been proposed as mechanisms of anemia of CKD. In normal individuals a low level of circulating erythropoietin (EPO) produced by the nephrons (10-30 mUnits/mL) is sufficient to maintain erythropoiesis. CKD patients do not have elevations of serum EPO levels that are seen in healthy individuals with comparable degree of anemia. The US FDA approved recombinant EPO in 1989. Since then, treatment with supra-physiologic doses of EPO has become the mainstay of anemia management in CKD. It has been estimated that at any given time 90% of prevalent dialysis patients require erythropoiesis-stimulating agents. Undifferentiated pluripotent stem cells, in the bone marrow are capable of producing committed erythroid colony forming units (CFU-E) under the influence of EPO. These cells ultimately differentiate into RBCs that are released into the circulation. Because of finite non-zero cell maturation and cell replication times there is a delay between EPO administration and RBC production. In healthy individuals the time needed for cell maturation in the marrow ranges from 6-10 days. The maturation of red cells in marrow of CKD patients has not been studied. We hypothesize that this maturation time is prolonged in patients with CKD. By identifying the existence of a delay in cell maturation we can begin to investigate the factors determining the delay. We may also be able to identify new targets for treatments of anemia in kidney disease by targeting cell maturation pathways. METHODS Mathematically, erythropoiesis can be formulated as a time model taking the form of a simple differential equation. Delay differential equations can be used to incorporate the delay in cell proliferation depicted by τ. The circulating erythrocytes are removed from the circulation at a rateγ. Therefore, 1/γ represents the life span of the erythrocyte. η and θ are shape parameters in the model and β (rate of RBC production) is a constant. This model was first proposed by Mackey and Glass and is popularly known as the Mackey-Glass Model. Monthly hemoglobin values were collected for 50 end stage renal disease patients on peritoneal dialysis over a period of 24-36 months. Individual models for each patient were developed in Mathematica v. 9.0. To obtain the best fit τ was progressively varied from 1-8 weeks till a good fit was achieved. γ was maintained in the range that represents expected RBC survival in these patients (range 7-14 weeks). RESULTS A representative model is shown in figure 1 below. We found τ to be significantly prolonged up to 6 weeks (mean 4 weeks, range: 1-6 weeks) in patients receiving peritoneal dialysis. This has important implications. A prolonged delay of up to 6 weeks in the effect of EPO can give rise to pseudo EPO-resistance. This phenomenon is clearly observed in clinical practice. Reactionary increase or reduction in EPO doses to apparent lack of response to EPO, leads to fluctuations in hemoglobin, a phenomenon that has been called hemoglobin cycling by clinical epidemiologists and has been related to mortality and cardiovascular outcomes. Recognition of the delay in cell maturation within the marrow which may show wide variation amongst patients (range 1-6 weeks); calls for individualizing drug treatment protocols rather than using population based algorithms. We also found evidence that patients with chronic renal failure are still capable of increasing their rate of red cell production in response to an increase in the rate of cell loss [Fig 2(a)]. Interestingly we found that the delay in cell maturation (τ) is prolonged when the basal erythropoietic rate (β) are increased [Fig 2(b)]. This effect is paradoxical since normal physiologic response to anemia should shorten cell transit times in face of increased demand. This leads us to hypothesize that cells may get arrested during their maturation. Increased levels of several inflammatory mediators may explain the maturation arrest. A lack of clear understanding of the factors affecting the maturation delay makes management of ESA-resistance challenging. New therapeutic approaches that target cellular pathways resulting in arrest of cellular maturation in the marrow may provide an avenue for new drug development. Figure 1. Figure 1. Figure 2. Figure 2. Disclosures No relevant conflicts of interest to declare.

Role of Thrombotic Risk Factors in End-Stage Renal Disease

2009 ◽  
Vol 16 (2) ◽  
pp. 132-140 ◽  
Author(s):  
Gaurav Tripathi ◽  
Satya Narayan Sankhwar ◽  
Raj Kumar Sharma ◽  
Vinod Pandirikkal Baburaj ◽  
Suraksha Agrawal
Keyword(s):  
Risk Factors ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Serum Folate ◽  
Coagulation Cascade ◽  
Factor V Leiden Mutation ◽  
Thrombotic Risk ◽  
Total Homocysteine ◽  
Stage Renal Disease ◽  
End Stage

Introduction: Genetic polymorphisms that are found among factors of the coagulation cascade are factor V leiden mutation (FVL), prothrombin (PT), and methylenetetrahydrofolate reductase (MTHFR), reported for thrombotic complications. We have investigated the associations of these gene polymorphisms in patients with end-stage renal disease (ESRD). Methods: We genotyped 258 patients for FV G1691A, PT G20210A, and MTHFR (C677T, A1298C) gene by using polymerase chain reaction—restriction fragment length polymorphism (PCR-RFLP) analysis and were compared with 569 healthy controls. Serum folate, total homocysteine (tHcys), and vitamin B12 were measured in both patients with ESRD and controls. Results: No homozygous individuals for the mutant AA genotype of FVL G1691A were observed in this study. The frequency of the heterozygous genotypes was (11.2%), which was nearly 3 times higher than that observed in controls (3.2%), with a odds ratio of 3.87 (P = .0001, 95% CI = 2.11-7.11). PT G20210A mutation was missing in both patients and the controls. At MTHFR locus, TT genotype of C677T was present in 9.6% among ESRD, while CC genotype of A1298C was present in 11.7% of the ESRD. In control group, it was significantly low that is, 4.2% and 3.2%, respectively (P = .0034; OR = 2.44, 95% CI = 1.36-4.36 and P < .0001; OR = 4.03; 95% CI = 2.2-7.37). The combined analysis of the 2 genotypes showed further increased risk in ESRD ~15 folds. Further, the carrier of TT and CC genotypes of C677T and A1298C had significantly higher total homocysteine (tHcys) level than those with CC and AA genotypes (P < .001). Conclusion: The carrier of FVL, TT genotype of C677T, and CC genotype of A1298C polymorphisms may act as risk factors for ESRD.

Sign in / Sign up

Export Citation Format

Share Document